307 related articles for article (PubMed ID: 37270060)
41. Early Fibrosis but Late Tumor Stage and Worse Outcomes in Hepatocellular Carcinoma Patients Without Hepatitis B or Hepatitis C.
Hsu PY; Hsu CT; Yeh ML; Huang CF; Huang CI; Liang PC; Lin YH; Hsieh MY; Wei YJ; Hsieh MH; Dai CY; Lin ZY; Chen SC; Huang JF; Yu ML; Chuang WL
Dig Dis Sci; 2020 Jul; 65(7):2120-2129. PubMed ID: 31722058
[TBL] [Abstract][Full Text] [Related]
42. Neutrophil: An emerging player in the occurrence and progression of metabolic associated fatty liver disease.
Chen S; Guo H; Xie M; Zhou C; Zheng M
Int Immunopharmacol; 2021 Aug; 97():107609. PubMed ID: 33887577
[TBL] [Abstract][Full Text] [Related]
43. The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease.
Pennisi G; Celsa C; Giammanco A; Spatola F; Petta S
Curr Pharm Des; 2020; 26(32):3928-3938. PubMed ID: 32436818
[TBL] [Abstract][Full Text] [Related]
44. MicroRNA-92b-3p promotes the progression of liver fibrosis by targeting CREB3L2 through the JAK/STAT signaling pathway.
Huang W; Ji R; Ge S; Zhou D; Liu Z; Sun Y; Huang W; Lu C
Pathol Res Pract; 2021 Mar; 219():153367. PubMed ID: 33618248
[TBL] [Abstract][Full Text] [Related]
45. Preoperative noninvasive assessment for liver fibrosis in hepatocellular carcinoma patients with chronic hepatitis B: Comparison of two-dimensional shear-wave elastography with serum liver fibrosis models.
Chen S; Jiang T
Eur J Radiol; 2020 Dec; 133():109386. PubMed ID: 33160197
[TBL] [Abstract][Full Text] [Related]
46. How effective are nonalcoholic fatty liver disease models for drug discovery?
Hundertmark J; Tacke F
Expert Opin Drug Discov; 2020 Nov; 15(11):1237-1240. PubMed ID: 32524859
[TBL] [Abstract][Full Text] [Related]
47. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer.
Tsuchida T; Lee YA; Fujiwara N; Ybanez M; Allen B; Martins S; Fiel MI; Goossens N; Chou HI; Hoshida Y; Friedman SL
J Hepatol; 2018 Aug; 69(2):385-395. PubMed ID: 29572095
[TBL] [Abstract][Full Text] [Related]
48. MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosis.
Fernández-Ramos D; Fernández-Tussy P; Lopitz-Otsoa F; Gutiérrez-de-Juan V; Navasa N; Barbier-Torres L; Zubiete-Franco I; Simón J; Fernández AF; Arbelaiz A; Aransay AM; Lavín JL; Beraza N; Perugorria MJ; Banales JM; Villa E; Fraga MF; Anguita J; Avila MA; Berasain C; Iruzibieta P; Crespo J; Lu SC; Varela-Rey M; Mato JM; Delgado TC; Martínez-Chantar ML
Cell Death Dis; 2018 Sep; 9(10):958. PubMed ID: 30237481
[TBL] [Abstract][Full Text] [Related]
49. Astragaloside IV inhibits hepatocellular carcinoma by continually suppressing the development of fibrosis and regulating pSmad3C/3L and Nrf2/HO-1 pathways.
Zhang C; Li L; Hou S; Shi Z; Xu W; Wang Q; He Y; Gong Y; Fang Z; Yang Y
J Ethnopharmacol; 2021 Oct; 279():114350. PubMed ID: 34157326
[TBL] [Abstract][Full Text] [Related]
50. Connective tissue growth factor (CTGF/CCN2) in serum is an indicator of fibrogenic progression and malignant transformation in patients with chronic hepatitis B infection.
Gressner OA; Fang M; Li H; Lu LG; Gressner AM; Gao CF
Clin Chim Acta; 2013 Jun; 421():126-31. PubMed ID: 23501329
[TBL] [Abstract][Full Text] [Related]
51. Hepatic fibrosis influences the growth of hepatocellular carcinoma.
Osada S; Kanematsu M; Imai H; Goshima S; Sugiyama Y
Hepatogastroenterology; 2008; 55(81):184-7. PubMed ID: 18507103
[TBL] [Abstract][Full Text] [Related]
52. Branched-chain amino acids prevent hepatic fibrosis and development of hepatocellular carcinoma in a non-alcoholic steatohepatitis mouse model.
Takegoshi K; Honda M; Okada H; Takabatake R; Matsuzawa-Nagata N; Campbell JS; Nishikawa M; Shimakami T; Shirasaki T; Sakai Y; Yamashita T; Takamura T; Tanaka T; Kaneko S
Oncotarget; 2017 Mar; 8(11):18191-18205. PubMed ID: 28212548
[TBL] [Abstract][Full Text] [Related]
53. Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation.
Jiang Y; Chen P; Hu K; Dai G; Li J; Zheng D; Yuan H; He L; Xie P; Tu M; Peng S; Qu C; Lin W; Chung RT; Hong J
J Cell Mol Med; 2021 Feb; 25(3):1568-1582. PubMed ID: 33410581
[TBL] [Abstract][Full Text] [Related]
54. Fibrosis-dependent mechanisms of hepatocarcinogenesis.
Zhang DY; Friedman SL
Hepatology; 2012 Aug; 56(2):769-75. PubMed ID: 22378017
[TBL] [Abstract][Full Text] [Related]
55. Portal vein embolization with N-butyl cyanoacrylate before partial hepatectomy in patients with hepatocellular carcinoma and underlying cirrhosis or advanced fibrosis.
Denys A; Lacombe C; Schneider F; Madoff DC; Doenz F; Qanadli SD; Halkic N; Sauvanet A; Vilgrain V; Schnyder P
J Vasc Interv Radiol; 2005 Dec; 16(12):1667-74. PubMed ID: 16371534
[TBL] [Abstract][Full Text] [Related]
56. Mouse Models of Liver Fibrosis.
Ravichandra A; Schwabe RF
Methods Mol Biol; 2021; 2299():339-356. PubMed ID: 34028753
[TBL] [Abstract][Full Text] [Related]
57. Assessing Hepatic Fibrosis Using 2-D Shear Wave Elastography in Patients with Liver Tumors: A Prospective Single-Center Study.
Huang Z; Zheng W; Zhang YJ; Xu L; Chen JB; Chen JC; Chen MS; Zhou Z
Ultrasound Med Biol; 2017 Nov; 43(11):2522-2529. PubMed ID: 28807448
[TBL] [Abstract][Full Text] [Related]
58. Hepatocellular carcinoma cells and their fibrotic microenvironment modulate bone marrow-derived mesenchymal stromal cell migration in vitro and in vivo.
Garcia MG; Bayo J; Bolontrade MF; Sganga L; Malvicini M; Alaniz L; Aquino JB; Fiore E; Rizzo MM; Rodriguez A; Lorenti A; Andriani O; Podhajcer O; Mazzolini G
Mol Pharm; 2011 Oct; 8(5):1538-48. PubMed ID: 21770423
[TBL] [Abstract][Full Text] [Related]
59. Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet.
Ganguly S; Muench GA; Shang L; Rosenthal SB; Rahman G; Wang R; Wang Y; Kwon HC; Diomino AM; Kisseleva T; Soorosh P; Hosseini M; Knight R; Schnabl B; Brenner DA; Dhar D
Cell Mol Gastroenterol Hepatol; 2021; 12(3):891-920. PubMed ID: 34062281
[TBL] [Abstract][Full Text] [Related]
60. Targeting Hepatic Stellate Cell Death to Reverse Hepatic Fibrosis.
Zhang X; Zeng Y; Zhao L; Xu Q; Miao D; Yu F
Curr Drug Targets; 2023; 24(7):568-583. PubMed ID: 36999702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
